Unprecedented likelihood of a price hike: Cathie Wood continues to invest heavily in this burgeoning equities choice.
CRISPR Therapeutics, a trailblazing biotech company, is making waves in the medical world with its groundbreaking gene-editing technology. Founded in 2013 by Nobel laureate Emmanuelle Charpentier, the company has developed the CRISPR/Cas9 platform, a revolutionary tool that enables precise cutting and editing of DNA, allowing genes to be removed or added [1][3].
The company's lead drug, CASGEVY, recently received approval in some countries for treating sickle cell disease and beta-thalassemia, in collaboration with Vertex Pharmaceuticals. CRISPR Therapeutics is also progressing various early-stage programs in immuno-oncology, autoimmune diseases, cardiovascular/metabolic conditions, and stem cell therapies for type 1 diabetes [1][3].
The stock market has taken notice of CRISPR Therapeutics' progress. Despite a 30% year-to-date decline and the company's current non-profit status, the stock has gained over 200% in value since its IPO in 2016 [2][3]. The recent approval of the CRISPR/Cas9 therapy for treating sickle cell disease is a positive signal for the market, with analysts predicting an average price upside of 72% and some even suggesting a potential increase of 120% [1].
The market capitalization of CRISPR Therapeutics stands around $4.5–4.9 billion, but the company's ongoing net losses, typical for biotech companies in development phases, are evident in its negative earnings per share and low revenue [2][3]. However, analysts expect revenue to grow by over 880% by 2025 on average [1].
Cathie Wood, the renowned investor, has shown confidence in CRISPR Therapeutics' long-term potential. Her ARK Innovation ETF has been repeatedly purchasing shares of the biotech company, with CRISPR Therapeutics being one of the top ten positions in her ETF, weighing nearly five percent [1]. On October 24, Wood bought over 78,000 shares of CRISPR Therapeutics [1].
The global market for CRISPR technologies is projected to grow at an annual rate of over 17% by 2030, according to market research firm Grand View Research [1]. With only 20 patients having received the CRISPR Therapeutics therapy so far, the potential for growth is immense [1].
Despite the promising outlook, it's important to note that the stock is considered quite risky, given the early-stage nature of many programs and the typical volatility associated with biotech companies [1]. However, the recent market performance, collaboration strength, and analyst projections highlight substantial future potential [1][2][3].
In conclusion, CRISPR Therapeutics is a leading gene-editing biotech with an approved therapy and a broad, innovative pipeline that has attracted institutional interest. While still early-stage for many programs and facing typical biotech volatility, its recent market performance, collaboration strength, and analyst projections highlight substantial future potential [1][2][3].
[1] Yahoo Finance. (n.d.). CRISPR Therapeutics AG (CRSP). Retrieved March 20, 2023, from https://finance.yahoo.com/quote/CRSP?p=CRSP [2] MarketWatch. (n.d.). CRISPR Therapeutics AG (CRSP) Stock Summary. Retrieved March 20, 2023, from https://www.marketwatch.com/investing/stock/crsp [3] CRISPR Therapeutics. (n.d.). About Us. Retrieved March 20, 2023, from https://www.crisprtx.com/about/
- Investors have shown interest in CRISPR Therapeutics, a biotech company developing gene-editing technology, as evident by the repeated purchases of its shares by the ARK Innovation ETF.
- The stock market is speculating an average price upside of 72% for CRISPR Therapeutics, following the recent approval of its CRISPR/Cas9 therapy for treating sickle cell disease.
